Artelo Biosciences (NASDAQ:ARTL) Releases Earnings Results, Beats Estimates By $0.06 EPS

Artelo Biosciences (NASDAQ:ARTL) posted its quarterly earnings data on Tuesday. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06, Zacks reports.

Artelo Biosciences Stock Performance

NASDAQ ARTL opened at $1.08 on Friday. Artelo Biosciences has a fifty-two week low of $1.00 and a fifty-two week high of $1.75. The business has a 50 day moving average price of $1.16 and a two-hundred day moving average price of $1.28.

Analyst Upgrades and Downgrades

ARTL has been the subject of a number of research reports. EF Hutton Acquisition Co. I upgraded Artelo Biosciences to a “strong-buy” rating in a report on Tuesday, October 1st. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Artelo Biosciences in a report on Wednesday.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.